The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Regeneron Announces Presentation at the 9th Annual Needham Healthcare Conference

Friday, June 04, 2010

Regeneron Announces Presentation at the 9th Annual Needham Healthcare Conference09:30 EDT Friday, June 04, 2010TARRYTOWN, N.Y., June 4 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 9th Annual Needham Healthcare Conference on Thursday, June 10, 2010. �The presentation is scheduled for 2:00 p.m. Eastern Time. �The session may be accessed through the Company's web site,, on the Investor Relations page. �An archived version of the presentation will be available after the live webcast through July 10, 2010. �Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. �In addition to ARCALYST� (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. �Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. �Additional information about Regeneron and recent news releases are available on Regeneron's web site at Information:Michael Aberman, M.D.Laura LindsayInvestor RelationsCorporate Communications914.345.7799 914.345.7800michael.aberman@regeneron.comlaura.lindsay@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.For further information: Michael Aberman, M.D., Investor Relations, +1-914-345-7799,, or Laura Lindsay, Corporate Communications, +1-914-345-7800,